Adaptive Biotechnologies Corporation (ADPT) News
Track canonical SquawkNews coverage tagged to ADPT, Adaptive Biotechnologies Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Adaptive Biotechnologies Price Target Announced at $35.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 10:59 AM UTC
L
Adaptogenics Health Corp. (ADPT) Closes $327K Private Placement at $0.08
Adaptogenics Health Corp. closed an oversubscribed non-brokered private placement of 4.09M shares at $0.08 for $327K. Two directors bought 750K shares; all shares carry a 4-month+1-day hold to Jan 29, 2027.Material Detai
EQUITY | Sep 28, 2026, 08:41 PM UTC
L
Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement
Vancouver, British Columbia--(. - September 28, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce that, further to its news release dated August 14, 2026, the Company ha
NEWS | Sep 28, 2026, 08:41 PM UTC
L
Weekly Recap: Q2 revenue up 22% and NCCN mentions clonoSEQ
Adaptive Biotechnologies Corp. (NASDAQ:ADPT) posted Q2 2026 revenue of $72M, up 22% YoY with core MRD revenue rising 33%, and the NCCN guideline now citing clonoSEQ for blood MRD in multiple myeloma could accelerate clin
EARNINGS | Sep 28, 2026, 11:06 AM UTC
L
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cellsSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -
NEWS | Sep 25, 2026, 12:08 PM UTC
L
Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical trials.CareDx Inc. (CDNA)C
NEWS | Sep 25, 2026, 08:54 AM UTC
M
Adaptive Biotechnologies cites NCCN MRD guidance update for clonoSEQ
Adaptive Biotechnologies says updated NCCN Guidelines for multiple myeloma now include a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared MRD assay, with 10-6 sensitivi
EQUITY | Sep 17, 2026, 12:03 PM UTC
L
ADPT - Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
ADPT - Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
NEWS | Sep 17, 2026, 12:00 PM UTC
L
ServiceTitan shares fall after fiscal Q2 results and weak Q3 guidance
ServiceTitan (TTAN) dropped in pre-market trading after reporting fiscal Q2 results for the quarter ended July 31, 2026, and issuing fiscal Q3 sales guidance with a midpoint below estimates.
EARNINGS | Sep 09, 2026, 12:02 PM UTC
L
Adaptive Biotechnologies to participate in Morgan Stanley 24th Global Healthcare Conference
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) said it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
ADPT - Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
ADPT - Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 01, 2026, 08:05 PM UTC
L
ADPT - Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
ADPT - Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 08:06 PM UTC
L
ADPT Adaptive Biotechnologies RESULTS: Q2, Q2 REV $71.553M vs. EST $65.9M, Q2 operating expenses $87.323M, Q2 Net Income $-39.941M, Q2 EPS $
ADPT Adaptive Biotechnologies RESULTS: Q2, Q2 REV $71.553M vs. EST $65.9M, Q2 operating expenses $87.323M, Q2 Net Income $-39.941M, Q2 EPS $-0.25, Q2 Operating Income $-15.77M, Q2 ADJ EBITDA $-700 thousand
EARNINGS | Jul 29, 2026, 08:06 PM UTC
L
Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing
() -- Harlan S Robins, Chief Scientific Officer, on July 02, 2026, sold 386,240 shares in Adaptive Biotechnologies (ADPT) for $8,501,149. Following the Form 4 filing with the SEC, Robins has control over a total of 1,019
REGULATION | Jul 08, 2026, 07:35 AM UTC
L
Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing
() -- Francis Lo, Chief People Officer, on July 01, 2026, sold 95,842 shares in Adaptive Biotechnologies (ADPT) for $2,157,683. Following the Form 4 filing with the SEC, Lo has control over a total of 233,213 common shar
REGULATION | Jul 07, 2026, 07:58 AM UTC